Edition:
India

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

3.99USD
1:30am IST
Change (% chg)

$-0.31 (-7.21%)
Prev Close
$4.30
Open
$4.30
Day's High
$4.31
Day's Low
$3.95
Volume
225,954
Avg. Vol
301,129
52-wk High
$8.75
52-wk Low
$2.06

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.59
Market Cap(Mil.): $396.17
Shares Outstanding(Mil.): 51.05
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.81 -- --
ROI: -73.69 14.84 14.38
ROE: -73.76 16.34 16.08

BRIEF-Tetraphase Pharma Q4 Loss Per Share $0.46

* TETRAPHASE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, HIGHLIGHTS ACHIEVEMENTS AND KEY 2018 MILESTONES

07 Mar 2018

BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline

* TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

27 Feb 2018

BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines

* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA

21 Feb 2018

Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

14 Feb 2018

BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI

* TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI)

14 Feb 2018

BRIEF-Tetraphase Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln

* FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2n8xDCf) Further company coverage:

26 Jan 2018

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

03 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $121.45 -0.59
Pfizer Inc. (PFE.N) $36.30 -0.16
Merck & Co., Inc. (MRK.N) $61.18 -0.10
AstraZeneca plc (AZN.L) 5,255.00 -124.00

Earnings vs. Estimates